A share price of Sarepta Therapeutics Inc [SRPT] is currently trading at $15.91, down -3.11%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SRPT shares have gain 33.36% over the last week, with a monthly amount drifted -12.56%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sarepta Therapeutics Inc [NASDAQ: SRPT] stock has seen the most recent analyst activity on July 29, 2025, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $37 for it. Previously, JP Morgan upgraded its rating to Neutral on July 29, 2025, and kept the price target unchanged to $24. On July 29, 2025, upgrade upgraded it’s rating to Equal Weight but maintained its price target of $22 on the stock. H.C. Wainwright reiterated its Sell rating but stick to its price target of $5 on July 29, 2025. Bernstein initiated its recommendation with a Mkt Perform and recommended $13 as its price target on July 29, 2025. Barclays downgraded its rating to Underweight for this stock on July 28, 2025, but kept the price target unchanged to $10. In a note dated July 25, 2025, JP Morgan downgraded an Underweight rating on this stock.
Sarepta Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $10.41 and $145.00. Currently, Wall Street analysts expect the stock to reach $41.86 within the next 12 months. Sarepta Therapeutics Inc [NASDAQ: SRPT] shares were valued at $15.91 at the most recent close of the market. An investor can expect a potential return of 163.1% based on the average SRPT price forecast.
Analyzing the SRPT fundamentals
Trailing Twelve Months sales for Sarepta Therapeutics Inc [NASDAQ:SRPT] were 2.23B which represents 80.15% growth. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -0.05%, Pretax Profit Margin comes in at -0.07%, and Net Profit Margin reading is -0.11%. To continue investigating profitability, this company’s Return on Assets is posted at -0.07, Equity is -0.2 and Total Capital is -0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.58 points at the first support level, and at 15.25 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.31, and for the 2nd resistance point, it is at 16.70.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Sarepta Therapeutics Inc [NASDAQ:SRPT] is 4.02. As well, the Quick Ratio is 2.46, while the Cash Ratio is 0.4. Considering the valuation of this stock, the price to sales ratio is 0.70, the price to book ratio is 1.37.
Transactions by insiders
Recent insider trading involved Nicaise Claude, Director, that happened on Mar 12 ’25 when 2491.0 shares were sold. Director, Nicaise Claude completed a deal on Mar 12 ’25 to buy 2491.0 shares. Meanwhile, Director Wigzell Hans Lennart Rudolf sold 10500.0 shares on Dec 12 ’24.
